The needle-free, painless, and cost-effective transdermal delivery system is expected to witness increase in demand in global CINV market.
The global CINV Market encompasses patient pool type and geography of the CINV drugs market. The patient pool type segment includes Aloxi (palonosetron), Kytril Generic (Granisetron), Emend (aprepitant), Netupitant-Palonosetron FDC, and others. Netupitant-palonosetron is the fastest growing therapy or drug type for this market owing to increasing adoption to CINV drugs with rising cancer patients going for chemotherapy treatment.
The global market is expected to garner $2,659 million by 2022, growing at a CAGR of 7.1% during 2016-2022.
The key impacting factors include growth in number of patients undergoing chemotherapy and the rising compliance to CNIV drugs due to increase in adoption of novel drug delivery methods such as combination therapies & transdermal patches. Further, the market is also influenced by technology developments to discover new high potential drugs, thus creating opportunity for the market growth. However, high price of CINV drugs restrict the growth.
Get the PDF brochure of this market insight@ https://www.alliedmarketresearch.com/request-sample/1846
Presently, patient pool segment witnesses a high rate of CINV drugs adoption due to increasing number of patients with side effects associated with chemotherapeutic drug use. Further, the development and launch of novel drug delivery methods for CINV drugs is expected to boost patient compliance rates and the demand for CINV drugs. In addition, improvement in the control of CINV has occurred with the use of aprepitant, the first agent available in the drug class of neurokinin-1 (NK-1). One of the potential factors that explain this suboptimal response is variability in genes encoding enzymes and proteins, which play a role in metabolism, transport, and receptors related to antiemetic drugs.
KEY FINDINGS OF THE CINV MARKET STUDY
- The Aloxi segment generated the highest revenue in the global market in 2015, accounting for over half of the total market.
- The Netupitant-Palonosetron FDC segment is the fastest growing segment at a CAGR of 10.8%.
The North American market has witnessed a significant growth in the recent years. Presently, it is the largest regional market for CINV drugs and its market share is anticipated by 2022. Asia-Pacific is the fastest growing market due to increase in the number of cancer population, high incidences of gastroenteritis and other diseases that lead to nausea and vomiting. This region boosts up the demand for antiemetic drug due to growth in demand for CINV drugs and is expected to fuel the market growth in this region.